CG Oncology (NASDAQ:CGON) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of CG Oncology (NASDAQ:CGON) in a research report sent to investors on Monday morning, Benzinga reports. HC Wainwright currently has a $75.00 price target on the stock.

Several other analysts have also recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of CG Oncology in a research note on Tuesday, February 20th. They issued a neutral rating and a $42.00 target price for the company. Morgan Stanley assumed coverage on CG Oncology in a report on Tuesday, February 20th. They issued an overweight rating and a $55.00 price objective on the stock. Finally, Cantor Fitzgerald reissued an overweight rating and issued a $75.00 price target on shares of CG Oncology in a report on Thursday, May 2nd.

CG Oncology Price Performance

Shares of NASDAQ CGON opened at $30.02 on Monday. The business’s fifty day moving average is $38.63. CG Oncology has a 1-year low of $28.55 and a 1-year high of $50.23.

Institutional Investors Weigh In On CG Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of CGON. TimesSquare Capital Management LLC purchased a new position in CG Oncology in the 1st quarter valued at approximately $9,837,000. Capstone Investment Advisors LLC acquired a new stake in CG Oncology in the first quarter valued at $806,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of CG Oncology in the first quarter valued at $492,000. 26.56% of the stock is currently owned by institutional investors and hedge funds.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.